These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. Podiwinsky F; Mentasti M; Riederer P; Birkmayer W Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602 [TBL] [Abstract][Full Text] [Related]
44. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897 [TBL] [Abstract][Full Text] [Related]
46. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363 [TBL] [Abstract][Full Text] [Related]
47. Reduction of hypoxia-induced disturbances by previous treatment with benserazide and L-dopa in rats. Boismare F; le Poncin M; Belliard JP; Hacpille L Experientia; 1975 Oct; 31(10):1190-1. PubMed ID: 1204736 [TBL] [Abstract][Full Text] [Related]
48. Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor. Doller HJ; Connor JD; Lock DR; Sloviter RS; Dvorchik BH; Vesell ES Drug Metab Dispos; 1978; 6(2):164-8. PubMed ID: 26532 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase. Waterhouse MJ; Chia YC; Lees GJ Mol Pharmacol; 1979 Jan; 15(1):108-14. PubMed ID: 423884 [No Abstract] [Full Text] [Related]
50. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Buck K; Ferger B Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284 [TBL] [Abstract][Full Text] [Related]
51. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549 [No Abstract] [Full Text] [Related]
52. Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study. Messiha FS Proc West Pharmacol Soc; 1977; 20():327-31. PubMed ID: 896840 [No Abstract] [Full Text] [Related]
53. [Pathochemical changes in the motor structures of the brain under the influence of the administration of L-DOPA preparations and their withdrawal (experimental research)]. Kukuev LA; Sergutina AV; Gershteĭn LM Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(5):28-32. PubMed ID: 7900446 [TBL] [Abstract][Full Text] [Related]
54. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)]. Faglioni P; Gasparini M; Spinnler H Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578 [TBL] [Abstract][Full Text] [Related]
56. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Alam M; Schmidt WJ Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640 [TBL] [Abstract][Full Text] [Related]
57. Reduction of rat brain CD8+ T-cells by levodopa/benserazide treatment after experimental stroke. Kuric E; Ruscher K Eur J Neurosci; 2014 Jul; 40(2):2463-70. PubMed ID: 24754803 [TBL] [Abstract][Full Text] [Related]
58. Methoxytyrosine formation as an indicator of catechol-O-methyltransferase activity in rat liver in vivo. Kehr W; Zimmermann R; Thiede M Naunyn Schmiedebergs Arch Pharmacol; 1977 Oct; 300(1):19-23. PubMed ID: 593428 [TBL] [Abstract][Full Text] [Related]
59. Interaction of N-(DL-seryl)N'-(2,3,4-trihydroxybenzyl)-hydrazine with L-dopa decarboxylase from pig kidney. Borri-Voltattorni C; Minelli A; Borri P Experientia; 1977 Feb; 33(2):158-60. PubMed ID: 300332 [No Abstract] [Full Text] [Related]
60. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]